Abstract
Several vaccines against SARS-CoV-2 have been granted emergency use authorization from the United States Food and Drug Administration and similar regulatory bodies abroad to combat the COVID-19 pandemic. While these vaccines have been shown to be extremely safe, transient side-effects lasting 24-48 hours post-vaccination have been reported. Here we conducted a retrospective analysis of 50977 subscribers to the WHOOP platform (33119 males, 17858 females; total of 65686 unique responses) who received either the AstraZeneca (AZ, n=2093), Janssen/Johnson & Johnson (J&J&J, n=3888), Moderna (n=23776; M1, 14553 first dose; M2, 9223 second dose), or Pfizer/BioNTech (n=35929; P&B1, 22387 first dose; P&B2, 13542 second dose) vaccines using data collected through April 14, 2021. Subjective reactogenicity was assessed using self-reported surveys. Results from these surveys indicated that the odds of self-reporting an adverse event after vaccination depend on gender, age, and manufacturer. Objectively measured cardiovascular (resting heart rate, RHR; heart rate variability, HRV) and sleep (total sleep duration, % light sleep, and % restorative sleep [a combination of REM and slow wave sleep]) metrics were assessed using a wrist-worn biometric device (Whoop Inc, Boston, MA, USA) and compared to the same day of the week, one week prior. Data are presented as a percent change from baseline ± 95% confidence intervals. On the night after vaccination, RHR was higher (AZ: 13.5±0.76%; J&J&J: 16.5±0.64%; M1: 2.86±0.19%; M2: 9.3±0.53%; P&B1: 1.18±0.14%; P&B2: 13.5±0.36%) and HRV (AZ: -21.8±1.47%; J&J&J: - 25.6±1.15%; M1: -4.8±055%; M2: -19.9±1.33%; P&B1: -1.7±0.45%; P&B2: 8.60±1.10%) was lower than baseline levels. As for sleep metrics, total sleep was lower after the AZ and J&J&J vaccines (AZ: -3.7±0.98%; J&J&J: -3.8±0.80%; M1: 0.94±0.32%; M2: 0.14±0.80%; P&B1: 1.10±0.25%; P&B2: 0.35±0.63%); for AZ, J&J&J and the second dose of Moderna and P&B, a greater percentage of sleep post-vaccination came from light sleep (AZ: 9.24±1.22%; J&J&J: 13.8±1.02%; M1: 1.73±0.40%; M2: 8.02±0.99%; P&B1: 0.44±0.31%; P&B2: 2.54±0.74%) and a lower percentage from restorative sleep (AZ: -9.21±1.27%; J&J&J: -12.6±1.00%; M1: 0.16±0.43%; M2: -8.31±1.05%; P&B1: 1.27±0.34%; P&B2: -1.36±0.83%) than the week prior. Across all objective metrics measured, there were general trends that indicated an attenuated response in older populations and a larger response after the second dose for the Pfizer/BioNTech and Moderna vaccines (AstraZeneca second dose not analyzed). Importantly, the effects of the vaccines on cardiovascular and sleep measures were transient and returned to baseline by the second night following vaccination (P > 0.05 or absolute Cohen’s d < 0.25). In summary, these results confirm the previously observed subjective symptomatology trends, and for the first time show that objectively measured cardiovascular and sleep parameters are altered the night after vaccination. Moreover, these results suggest that the response may be different between vaccine manufacturers and may be modified by age and larger after the second dose. This information can be used to inform policy makers and employers considering offering paid time off for vaccination, as well as individuals planning their commitments post-vaccination.
Competing Interest Statement
All authors are affiliated with the commercial company WHOOP, Inc.
Funding Statement
The authors did not receive specific funding for this work. However both authors are affiliated with the commercial company WHOOP, Inc. which provided support in the form of salaries but did not otherwise play a role in the study design, data collection or analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study met criteria for exemption from IRB approval as determined by Advarra's IRB board (Pro00053755; IRB registration number: 00000971) due to the use of appropriately anonymized data accessed without the inclusion of personally identifiable information.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Public data sharing for these purposes is ethically and legally restricted. The data is collected and used with the consent of individuals who purchase a WHOOP membership (collectively, "WHOOP Members") and agree to the WHOOP terms of use (https://www.whoop.com/termsofuse/) and privacy policy (https://www.whoop.com/privacy/full-privacy-policy/). While WHOOP terms of use and privacy policy permit WHOOP to use collected data that has been aggregated or de-identified in a manner that no longer identifies an individual for informational purposes, analytics or WHOOP's own research purposes, the consent obtained from WHOOP Members does not extend to making the data publicly available for a third party to use for its own purposes. As such, WHOOP's legal department will not permit the data to be shared for these purposes.
